Evaxion A/S (EVAX) Expected to Announce Earnings on Thursday

Evaxion A/S (NASDAQ:EVAX) is projected to release its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Evaxion A/S to announce earnings of ($0.01) per share and revenue of $6.70 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 20, 2026 at 8:30 AM ET.

Evaxion A/S (NASDAQ:EVAX) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.43). On average, analysts expect Evaxion A/S to post $-0 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Evaxion A/S Price Performance

Shares of NASDAQ EVAX opened at $2.98 on Thursday. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.41. The stock has a fifty day simple moving average of $3.28 and a two-hundred day simple moving average of $3.63. Evaxion A/S has a 1-year low of $2.52 and a 1-year high of $12.15. The firm has a market cap of $24.85 million, a price-to-earnings ratio of -2.03 and a beta of 0.29.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on EVAX shares. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Evaxion A/S in a research note on Friday, April 24th. Weiss Ratings raised shares of Evaxion A/S from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Institutional Investors Weigh In On Evaxion A/S

A hedge fund recently bought a new stake in Evaxion A/S stock. Northwestern Mutual Wealth Management Co. purchased a new position in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 8,000 shares of the company’s stock, valued at approximately $38,000. Northwestern Mutual Wealth Management Co. owned 0.10% of Evaxion A/S at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.